TY - JOUR
T1 - Virotherapy using Myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells
AU - Bartee, Eric
AU - Meacham, Amy
AU - Wise, Elizabeth
AU - Cogle, Christopher R.
AU - McFadden, Grant
PY - 2012/8/14
Y1 - 2012/8/14
N2 - Graft-versus-host disease (GVHD) is a potentially lethal clinical complication arising from the transfer of alloreactive T lymphocytes into immunocompromised recipients. Despite conventional methods of T cell depletion, GVHD remains a major challenge in allogeneic hematopoietic cell transplant. Here, we demonstrate a novel method of preventing GVHD by ex vivo treatment of primary human hematopoietic cell sources with myxoma virus, a rabbit specific poxvirus currently under development for oncolytic virotherapy. This pretreatment dramatically increases post-transplant survival of immunocompromised mice injected with primary human bone marrow or peripheral blood cells and prevents the expansion of human CD3+ lymphocytes in major recipient organs. Similar viral treatment also prevents human-human mixed alloreactive T lymphocyte reactions in vitro. Our data suggest that ex vivo virotherapy with myxoma virus can be a simple and effective method for preventing GVHD following infusion of hematopoietic products containing alloreactive T lymphocytes such as: allogeneic hematopoietic stem and progenitor cells, donor leukocyte infusions and blood transfusions.
AB - Graft-versus-host disease (GVHD) is a potentially lethal clinical complication arising from the transfer of alloreactive T lymphocytes into immunocompromised recipients. Despite conventional methods of T cell depletion, GVHD remains a major challenge in allogeneic hematopoietic cell transplant. Here, we demonstrate a novel method of preventing GVHD by ex vivo treatment of primary human hematopoietic cell sources with myxoma virus, a rabbit specific poxvirus currently under development for oncolytic virotherapy. This pretreatment dramatically increases post-transplant survival of immunocompromised mice injected with primary human bone marrow or peripheral blood cells and prevents the expansion of human CD3+ lymphocytes in major recipient organs. Similar viral treatment also prevents human-human mixed alloreactive T lymphocyte reactions in vitro. Our data suggest that ex vivo virotherapy with myxoma virus can be a simple and effective method for preventing GVHD following infusion of hematopoietic products containing alloreactive T lymphocytes such as: allogeneic hematopoietic stem and progenitor cells, donor leukocyte infusions and blood transfusions.
UR - http://www.scopus.com/inward/record.url?scp=84865052411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865052411&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0043298
DO - 10.1371/journal.pone.0043298
M3 - Article
C2 - 22905251
AN - SCOPUS:84865052411
SN - 1932-6203
VL - 7
JO - PloS one
JF - PloS one
IS - 8
M1 - e43298
ER -